Functional and binding studies of insurmountable antagonism of 606A, a novel AT1-receptor antagonist in rabbit tissues

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 132-138

  Kurosawa, Yukie ^a   Minami, Kohichi ^a   Hashimoto, Yoshihiro ^a   Narita, Hiroshi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Angiotensin AT1 receptor antagonist; Angiotensin receptor; Insurmountable antagonism; Kinetics

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 4' [(2 CYCLOPROPYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL][1,1' BIPHENYL] 2 CARBOXYLIC ACID; 5 ACETYL 4,5,6,7 TETRAHYDRO 2 PROPYL 3 [2' (1H TETRAZOL 5 YL) 4 BIPHENYLYLMETHYL]IMIDAZO[4,5 C]PYRIDINE 4 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG COMPETITION; DRUG POTENCY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASOCONSTRICTION;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BINDING SITES; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RABBITS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0032987069     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00021     Document Type: Article

References (27)

1. Timmermans PB, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12:55-62.
2. Carini DJ, Duncia JV, Aldrich PE, et al. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem 1991;34:2525-47.
3. 3H]Dup 753: a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. Biochem Biophys Res Commun 1990;172:1195-202.
4. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-42.
5. Brunswig SB, Mukhopadhyay AK. Characterization of angiotensin-II receptor subtype on bovine thecal cells and its regulation by luteinizing hormone. Endocrinology 1992;131:1445-52.
6. Wexler RR, Carini DJ, Duncia JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992;5(12 Pt 2):S209-20.
7. Wong PC, Price WA, Chiu AT, et al. In vivo pharmacology of DuP 753. Am J Hypertens 1991;4(4 Pt 2):S288-98.
8. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987;8:69-74.
9. Regitz ZV, Neuss M, Holzmeister J, Fleck E. Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. J Hypertens 1995;13(1 Pt 1):S63-71.
10. Kino H, Hama J, Takenaka T, et al. Effect of angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury. Blood Press Suppl 1994;5:43-8.
11. Guddum JH, Hameed KA, Hathaway DE, Stephens FF. Quantitative studies of antagonists for 5-hydroxytryptamine. J Exp Physiol 1995;40:49-74.
12. Wong PC, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J Pharmacol Exp Ther 1991;258:49-57.
13. Chiu AT, Carini DJ, Duncia JV, et al. DuP 532: a second generation of nonpeptide angiotensin II antagonists. Biochem Biophys Res Commun 1991;177:209-17.
14. 8]AneII, for receptor blockade. J Pharmacol Methods 1988;20:207-24.
15. Courcelles DC, Leysen JE, Roevens P, Belle H. The serotonin-S2 receptor: a receptor transducer coupling model to explain insurmountable antagonist effects. Drug Dev Res 1986;8:173-8.
16. Wienen W, Mauz AB, Van Meel JC, Entzeroth M. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol Pharmacol 1992;41:1081-8.
17. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists: XI. pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-7.
18. Noda M, Shibouta Y, Inada Y, et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993;46:311-8.
19. Okunishi H, Song K, Oka Y, Kobayashi T, Kawamoto T, Ishihara H. In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177. Jpn J Pharmacol 1993;62:239-44.
20. Pendleton RG, Gessner G, Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal and aorta. J Pharmacol Exp Ther 1989;248:637-43.
21. Schild H. A new scale for the measurement of drug antagonism. Br J Pharmacol 1947;2:189-206.
22. Ariens EJ, van Rossum JM. pDx, pAx and pD'x values in the analysis of pharmacodynamics. Arch Int Pharmacodyn 1957;110: 275-99.
23. Hodges JC, Hamby JM, Blankley CJ. Angiotensin II receptor binding inhibitors. Drugs Future 1992;17:575.
24. Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ. In vivo pharmacology of L-158,809: a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992;262:139-14.
25. Hara M, Kiyama R, Nakajima S, et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol 1995;289:267-73.
26. Wong PC, Timmermans PBMW. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J Pharmacol Exp Ther 1991;258:49-57.
27. 1 antagonism. J Pharmacol Exp Ther 1995;273:753-61.